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Abstract
Background: In order to improve assessment and outcome prediction in patients suffering from traumatic brain
injury (TBI), cerebral protein levels in serum have been suggested as biomarkers of injury. However, despite much
investigation, biomarkers have yet to reach broad clinical utility in TBI. This study is a 9-year follow-up and clinical
experience of the two most studied proteins, neuron-specific enolase (NSE) and S100B, in a neuro-intensive care TBI
population. Our aims were to investigate to what extent NSE and S100B, independently and in combination, could
predict outcome, assess injury severity, and to investigate if the biomarker levels were influenced by extracranial
factors.
Methods: All patients treated at the neuro-intensive care unit at Karolinska University Hospital, Stockholm, Sweden
between 2005 and 2013 with at least three measurements of serum S100B and NSE (sampled twice daily) were
retrospectively included. In total, 417 patients fulfilled the criteria. Parameters were extracted from the computerized
hospital charts. Glasgow Outcome Score (GOS) was used to assess long-term functional outcome. Univariate, and
multivariate, regression models toward outcome and what explained the high levels of the biomarkers were
performed. Nagelkerke’s pseudo-R2 was used to illustrate the explained variance of the different models. A sliding
window assessed biomarker correlation to outcome and multitrauma over time.
Results: S100B was found a better predictor of outcome as compared to NSE (area under the curve (AUC) samples,
the first 48 hours had Nagelkerke’s pseudo-R2 values of 0.132 and 0.038, respectively), where the information
content of S100B peaks at approximately 1 day after trauma. In contrast, although both biomarkers were
independently correlated to outcome, NSE had limited additional predictive capabilities in the presence of S100B in
multivariate models, due to covariance between the two biomarkers (correlation coefficient 0.673 for AUC
48 hours). Moreover, NSE was to a greater extent correlated to multitrauma the first 48 hours following injury,
whereas the effect of extracerebral trauma on S100B levels appears limited to the first 12 hours.
Conclusions: While both biomarkers are independently correlated to long-term functional outcome, S100B is found
a more accurate outcome predictor and possibly a more clinically useful biomarker than NSE for TBI patients.
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Background
Worldwide, traumatic brain injury (TBI) is a major cause
of death and disability with an estimate of 10 million
affected annually, among whom many survive but with
lifelong disabilities [1]. Due to sociodemographic
changes, the burden of TBI is changing more from the
young to the already frail elderly, with increasing costs
for society [2, 3]. Patients suffering from severe TBI are,
often following neurosurgical intervention, usually se-
dated and treated in neuro-intensive care units (NICU)
where they are monitored and treated in order to
optimize intracranial conditions and facilitate recovery.
Parameters such as intracranial pressure (ICP) [4], me-
tabolism (using microdialysis monitoring) [5], and brain
oxygen saturation [6] are monitored and changes may
prompt responses in treatment strategies. Unfortunately,
many TBI patients still suffer from secondary insults
that may result in persistent secondary injuries [7, 8].
Thus, better monitoring, outcome prediction, and injury
stratification is necessary in order to optimize resource
allocation, to guide treatment, and to prevent further
deterioration.
In order to facilitate this, serum biomarkers have been
introduced in the field of TBI, where the proteins S100B
and neuron-specific enolase (NSE) are the most studied
[9]. S100B is a calcium-binding protein present primarily
in the cytoplasm of mature perivascular astrocytes [10].
Increased serum levels of S100B in serum have been
correlated to pathology on computed tomography (CT)
scans in mild TBI [11], to unfavorable long-term
functional outcome following moderate-to-severe TBI
[12–14] and may indicate a development of secondary
injuries in TBI patients [15, 16]. However, S100B is also
present in other nonneuronal tissue, primarily in mela-
nocytes, adipose tissue, cartilage, bone, liver, and myo-
cytes [17]. NSE is an enzyme involved in glycolysis in
both neuronal cells and erythrocytes, and elevated serum
levels have been shown to correlate to unfavorable out-
come and clinical complications in the NICU [18–21].
Biomarkers have the advantage of being more “global”
monitoring markers of brain injury than microdialysis
and oxygen saturation, which only detects changes in a
limited cerebral region. However, neither S100B or NSE
are 100 % brain specific, and extracranial sources will
contribute to total serum levels if patients suffer from
severe multitrauma or, in the case of NSE, hemolysis
[22–27]. In aggregate, while both S100B and NSE shows
promising results as predictive markers of outcome and
brain injury severity, they appear to be nonspecific to
TBI and the effect of this on their interpretation needs
to more thoroughly investigated.
The timing of S100B sampling in relation to that of
the trauma plays a crucial role when it is used to predict
long-term outcome, and several current studies suggest
that samples acquired hours or even days after trauma
are better for outcome prediction than samples acquired
at admission [12, 18, 28, 29]. In contrast, less is known
about how the predictive power of NSE changes over
time [18]. The serum half-life for S100B, without cere-
bral contribution, is considered to be around 25 minutes
while that of NSE is 30 hours [24, 30], which theoretic-
ally should influence outcome predictive capabilities and
optimal timing of sampling.
At our institution, we have sampled both S100B and
NSE routinely since 2005 resulting in an extensive data-
base comprising, to our knowledge, the largest clinical
set of NSE and S100B in TBI patients to date.
Methods
Aims
The primary aim of this study was to assess how serum
NSE, independently and together with S100B, correlated
to long-term functional outcome. As a secondary aim,
we investigated how multitrauma and other factors in-
fluenced the biomarker levels over time.
Study design
This is a database study of S100B and NSE levels col-
lected prospectively from patients admitted to the NICU
at Karolinska University Hospital from January 1, 2005
to December 31, 2013. The current study was approved
by the Regional Ethical Review Board in Stockholm
County (#2014/791-31/1). Using the TBI database regis-
tered by the Department of Clinical Neuroscience,
Section for Neurosurgery, there were 1128 patients be-
tween 2005 and 2013 with an International Classification
of Disease (ICD) 10 code S06.XX (traumatic intracranial
injury). Inclusion criteria were; age ≥18 years, at least
three measurements of S100B and NSE, where the first
sample had to be obtained within 48 hours and three
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samples within 72 hours after trauma. Moreover, the ad-
mission CT scan had to be available and the long-term
functional outcome had to be evaluated ≥3 months after
the trauma. Parts of this patient material have been used
in three previous publications by our group, then focus-
ing on S100B and neurofilament light [12, 15, 31].
Treatment
At our NICU, we adhere to guidelines similar to that of
the Brain Trauma Foundation [32, 33]. If mass lesions
are present, they are evacuated if deemed appropriate by
the attending neurosurgeon. To measure intracranial
pressure (ICP), ventricular catheters were predominantly
used, even if other pressure devices were sometimes uti-
lized (Codman Neuro, DePuy Synthes Companies of
Johnson & Johnson, New Brunswick, NJ, USA or Rehau
AG & Co, Bern, Germany). The ICP was targeted below
the threshold of 20 mmHg. The head of the patients was
elevated at a 30-degree angle with the measuring device
set at the temple. In case of intracranial hypertension or
autonomic dysfunction, cerebral perfusion pressure (CPP)
was used to guide treatment, targeted at 50–70 mmHg
calculated by using mean arterial pressure (MAP) – ICP.
CPP control was obtained by using vasopressors or intra-
vascular infusions. Unconscious patients were intubated,
mechanically ventilated, and anesthetized with morphine,
propofol, or midazolam. For patients with refractory high
ICP, barbiturate coma (monitored and limited by burst-
suppression on electroencephalogram) or hemicraniect-
omy was performed. Patients with traumatic subarachnoid
hemorrhage (trSAH) were monitored with transcranial
doppler and if signs of vasospasms were detected, treated
with intravascular infusion of the calcium antagonist
nimodipine [34]. Body temperature was targeted at
36–37 °C, regulated predominantly with paracetamol,
and occasionally parecoxib or Thermowrap® treatment
(MTRE Advanced Technologies Ltd., Yavne, Israel).
Clinical parameters
Scene-of-accident hypoxemia was defined as an oxygen
saturation <90 % and hypotension as a systolic blood
pressure <90 mmHg. Age and gender were noted. Multi-
trauma was defined according to Advanced Trauma and
Life Support (ATLS) guidelines, with a trauma to any
other organ apart from head or cervical injuries [35]. In
contrast to the Abbreviated Injury Score (AIS) [36], it
provides a cruder measurement of extracranial trauma.
However, as AIS is a product of events during the hos-
pital stay, we believe this to be a more accurate defin-
ition in the emergency setting. Admission glucose and
hemoglobin were recorded. If fluids had been provided
in the prehospital setting, hemoglobin levels at the scene
of accident were used, if available. Glasgow Coma Scale
(GCS) [37] was assessed at hospital admission and was
used as a continuous variable as previously described
[38, 39]. Pupil responsiveness was assessed as either both
responsive, unilateral unresponsive or bilateral unre-
sponsive. The maximum AIS score for the head injury
was noted for each patient after discharge, assessed by
nurses with special training in AIS grading [36].
Neuroradiology
The admission CT scan was assessed according to the
Marshall Classification [40], as well as the Rotterdam
and Stockholm CT score [41, 42], by a person blinded to
other clinical data. The Marshall classification is more
focused on the type of injury while the Rotterdam and
Stockholm CT scores focus on parameters correlated to
outcome. The Stockholm CT score has a subcomponent
of assessing the degree of subarachnoid hemorrhage
(Stockholm SAH), which was also used in isolation in
the analyses. The time from reported trauma to CT
examination was noted.
S100B and NSE analyses
As per clinical protocol since 2005, all TBI patients in
our NICU have S100B and NSE sampled at admission
and twice daily (06:00 and 18:00). From 2005 up until
September 2008, the serum samples of S100B were ana-
lyzed at the Department of Clinical Chemistry, Karo-
linska University Hospital (fully blinded from any
patient characteristic), using a quantitative automated
immunoassay (LIAISON, DiaSorin, Saluggia, Italy). After
that, the department changed method to an automated
electrochemoluminescence assay (Modular E170, Elecsys,
Roche Diagnostics, Basel, Switzerland) throughout the
study period. S100B has been shown not to be signifi-
cantly influenced by sample hemolysis [25].
NSE was analyzed throughout the whole period at the
Department of Clinical Chemistry, Karolinska University
Hospital, using a quantitative automated immunoassay
(LIAISON, DiaSorin, Saluggia, Italy). Samples were not
analyzed if the amount of hemoglobin exceeded 0.5 g/L
which was assessed visually using a hemolysis scale. If
the laboratory personnel determined that the amount of
hemoglobin exceeded 0.5 g/L, the sample was discarded.
The NSE samples were acquired simultaneously as
S100B.
The samples were sent to the Department of Clinical
Chemistry for immediate analysis. The admission sample
was usually from a venous source while the subsequent
samples were from arterial lines. The first three samples
and the area under curve (AUC), calculated using these
samples during the first 48 hours, were used. The lowest
levels of detection (LLOD) are 0.02 μg/L for S100B and
0.04 μg/L for NSE on the LIAISON assay, and
<0.005 μg/L for S100B on the Elecsys device. However,
the lowest level of quantification (LLOQ, also known as
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functional sensitivity) has been shown to be 0.02 μg/L
and 0.04 μg/L for S100B and NSE on the LIAISON,
respectively, as well as <0.02 μg/L on the Elecsys assay,
while lower concentrations sometimes also yield accept-
able coefficients of variation [43–45]. Thus, all detection
and quantification limits were lower than what were
detected in our patient material, and we do not believe
that the quantification range of the assays significantly
altered our findings. The reference levels for healthy
controls are generally considered to be <0.1 μg/L for
S100B [11] and <13 μg/L for NSE [46], respectively.
Long-term functional outcome
At our institution, the five-step Glasgow Outcome Score
(GOS) [47] is assessed at discharge, after 3–6 months as
the patient visits the operating physician in the clinic or
at the rehabilitation facility and after 12 months through
a questionnaire regarding quality of life. GOS1 = dead,
GOS2 = vegetative state, GOS3 = severe, dependent state,
GOS4 =moderately recovered, independent state and
GOS5 = good recovery. The latest available GOS was
used and surviving patients with GOS evaluation
<3 months after trauma were excluded.
Statistical analysis
The collected data are presented as median and inter-
quartile range (IQR) for continuous data and grouped
for categorical data. Several parameters were not nor-
mally distributed, including the biomarkers, and were
logged to approach to normal distribution. In univariate
logistic regression toward outcome (“rms” package in R),
the parameters were analyzed individually versus either
GOS1–5 (proportional odds analysis), GOS1–3 (unfavor-
able) versus GOS4–5 (favorable), or GOS1 (dead) versus
GOS2–5 (alive). A step-up multivariate analysis was
used to determine if different parameters added signifi-
cantly explained the variance to the different models. We
included the same parameters that are used in the Inter-
national Mission for Prognosis and Analysis of Clinical
Trials in TBI (IMPACT) calculator to determine long-
term functional outcome after TBI [48]. Nagelkerke’s
pseudo-R2 was used to determine model accuracy of bino-
mial and proportional odds analyses models and adjusted
R2 that of linear correlations, where appropriate. A sliding
window assessing a proportional odds analysis of S100B
and NSE toward GOS with bootstrapped confidence inter-
vals used to explore prediction accuracy over time in rela-
tion to the trauma. The same approach was used to assess
how multitrauma influenced S100B and NSE levels over
time. The R package “ggplot2” was used to illustrate the
data [49]. Linear models were used to determine what
factors that contributed both in univariate and in multi-
variate analyses to the levels of NSE and S100B, and the
resulting adjusted R2 was provided. The statistical
program R was used in the analyses (RStudio version
0.99.486 using version 3.2.2 of R, Boston, MA, USA) [50].
A p value of <0.05 was considered significant.
Missing data
Univariate regression models toward outcome are shown
for un-imputed data. Multivariate prediction models
were performed using the Multiple Imputation (MI)
(MICE package, R), as advocated in the statistical litera-
ture [51] and suggested by the IMPACT TBI study
group [52]. MI commonly uses seven imputed sets of
data, where the imputed data comes from a regression
and each imputed data differs - drawn from a distribu-
tion. The purpose of this is to retain the uncertainty
caused by imputation in the analyses. This method has
been shown to handle up to 50 % imputed data with
limited introduction of bias. Unfortunately, AIS grading
started in January 2006 at our institution so this infor-
mation was not available for patients in 2005 (n = 72)
and was among the data that was more highly imputed,
and will due to the time component, to some extent,
violate the missing at random assumption.
Results
Patient characteristics
Out of 1128 patients, 417 patients fulfilled the inclusion
criteria. A majority of the excluded patients did not have
enough samples (n = 593), while some were <18 years
old (n = 47), had too early a GOS assessment (n = 35),
had missing time of trauma (n = 31), or an admission
CT scan from another primary hospital that could not
be obtained (n = 5). Among the 593 patients with too
few samples, 24 patients were excluded due to early
death. Patient demographics are illustrated in Table 1.
Our inclusion criteria excluding patients with short ICU
stay and predominantly higher GCS patients rendered
almost all eligible patients to be classified as Head
AIS ≥3, or a “serious” TBI, which coincided with that
a majority also were unconscious at admission to the hos-
pital (GCS3–8, 66 %). “Diffuse injury”, according to the
Marshall CT classification, was present in 35 %, while
65 % had injuries >25 mL (“focal injury”, grade VI). Al-
most 20 % of the patients had hemolysis in their NSE
samples the first 72 hours. Outcome was assessed at ap-
proximately 1 year in a majority of cases (median days
from trauma = 368), and was almost equally distributed
between favorable (GOS4–5) (n = 214, 51 %) and unfavor-
able (GOS1–3) (n = 203, 49 %). The mortality rate of the
included patients was 20 %.
Univariate analyses toward long-term outcome
Known outcome predictors of TBI such as age, pupil re-
sponsiveness, and GCS were all significant in univariate
analysis and had an expected high pseudo-R2 (Table 2).
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Table 1 Patient demographics
Parameter Category Data Missing, n (%)
Age, years Median (IQR) 52 (34–62)
Gender Male/female, n (%) 332/85 (80/20)
Scene of accident
Multitrauma n (%) 131 (31) 2 (0.5)
Hypoxemia (oxygen saturation <90 %) n (%) 47 (11) 115 (28)
Hypotension (systolic blood pressure <90 mmHg) n (%) 11 (3) 118 (28)
Admission
Glasgow Coma Score (GCS) GCS 3–8, n (%) 274 (66)
GCS 9–13, n (%) 105 (25)
GCS 14–15, n (%) 38 (9)
Pupil unresponsiveness, Out of total, n (%) 93 (22) 13 (3)
Unilateral unresponsiveness, n (%) 53 (13)
Bilateral unresponsiveness, n (%) 40 (10)
Hemoglobin (g/L) Median (IQR) 136 (121–147) 19 (5)
Glucose (mmol/L) Median (IQR) 8.0 (7.0–9.8) 99 (24)
Time from trauma to sampling (hh:mm) Median (IQR) 01:05 (00:45–03:39)
Head Abbreviated Injury Score (AIS) 2, n (%) 1 (0.2) 77 (18)
3, n (%) 40 (10)
4, n (%) 119 (29)
5, n (%) 177 (42)
6, n (%) 3 (1)
Radiology
Marshall CT Classification I (Diffuse injury), n (%) 1 (0.2)
II (Diffuse injury), n (%) 110 (26)
III (Diffuse injury), n (%) 34 (8)
IV (Diffuse injury), n (%) 1 (0.2)
VI (Focal injury), n (%) 271 (65)
Rotterdam CT Score 1, n (%) 10 (2)
2, n (%) 39 (9)
3, n (%) 155 (37)
4, n (%) 116 (28)
5, n (%) 80 (19)
6, n (%) 17 (4)
Stockholm Score Median (IQR) 2.5 (2.0–3.5)
Time from trauma to examination (hh:mm) Median (IQR) 01:32 (01:09–02:23)
Biomarkers
Time from trauma to admission sample (hh:mm) Median (IQR) 07:14 (02:40–13:27)
S100B (μg/L), admission Median (IQR) 0.57 (0.26–1.4)
Neuron-specific enolase (NSE) (μg/L), admission Median (IQR) 21 (15–31)
Time from trauma to second sample (hh:mm) Median (IQR) 17:30 (10:51–26:39)
S100B (μg/L), second sample Median (IQR) 0.38 (0.20–0.78)
NSE (μg/L), second admission Median (IQR) 19 (14–26)
Time from trauma to third sample (hh:mm) Median (IQR) 30:29 (22:30–42:09)
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S100B AUC 48 h exhibited a pseudo-R2 of 0.132, on par
with Stockholm CT score and surpassed only by age
(0.151). S100B showed better discrimination between all
the different dichotomizations of outcome, whereas NSE
is best at differentiating mortality (GOS1 vs. 2–5). The
values of S100B and NSE over time for individual pa-
tients are shown in Fig. 1. In general, high or increasing
levels are more correlated to a more unfavorable out-
come, something that is better visualized for S100B
(Fig. 1a) than for NSE (Fig. 1b). Similar to what was seen
in Table 2, when the biomarker levels for the specific
outcome groups were aggregated, S100B exhibits better
discrimination between different levels of GOS, espe-
cially 24–36 hours after trauma (Fig. 1c), while NSE was
only discriminates GOS1 as compared to GOS3–5
(Fig. 1d). GOS2 was excluded in Fig. 1c-d since only two
patients were assessed as vegetative at long-term follow-
up. S100B AUC 48 h (Fig. 2a) and NSE AUC 48 h
(Fig. 2b) highlights the biomarker levels in different
GOS groups, using conditional density plots (Fig. 2).
Optimal time point for outcome prediction
A sliding window using a proportional odds analysis to-
ward GOS1–5 indicated that the level of S100B’s relation
to outcome increased substantially after 12 hours (as
previously described [12]) and reached a pseudo-R2 of
>0.25 at approximately 30 hours (Fig. 1e), coinciding
with the mean peak time of the extended release of
S100B in TBI patients at 27 hours (accepted manu-
script). In contrast, an optimal time point for sampling
NSE in relation to outcome could not be identified and
remained low, <0.1 pseudo-R2 (Fig. 1f ), at all time
points. Additionally, the effect of multitrauma on bio-
marker levels over time was explored in the same man-
ner with a sliding window, revealing that the effect of
multitrauma is limited to the first 12 hours for S100B,
but is more pronounced and extended for NSE, (Fig. 1g
and h) clearly indicating a risk of late confounding using
this biomarker.
Multivariate prediction models toward long-term func-
tional outcome
A Core model was created using the parameters used in
the IMPACT calculator (using the Rotterdam CT score
instead of individual CT parameters) [48] (Table 3). This
exhibited a pseudo-R2 of 0.298 in prediction of GOS1–5.
As the Stockholm CT score constituted a higher pseudo-
R2 in univariate models, it replaced the Rotterdam CT
score in our Core model, which thus yielded a total
pseudo-R2 of 0.316. AUC levels of the biomarkers were
used. If S100B AUC was added to the Core model, a
pseudo-R2 of 0.379 was reached, significantly better than
the Core model (p <0.001). A similar significant increase
was seen if NSE AUC was added per se, albeit less than
S100B (0.379 vs 0.344 respectively). A glial:neuronal ra-
tio between S100B:NSE (S100B AUC/NSE AUC) did not
increase the explained variance as compared to if S100B
was used alone (pseudo-R2 0.365). If a prediction model
consisted of Core parameters + S100B, NSE did not en-
hance outcome prediction (p = 0.934). Age, pupil respon-
siveness, GCS, and Stockholm CT score remained
independently correlated to outcome in all models while
glucose levels, hemoglobin levels, and hypoxemia con-
tributed independently variably in models. In aggregate,
the Core model with the addition of S100B AUC was
the best predictive model.
Correlation between S100B and NSE levels
Admission levels of logged S100B and NSE were signifi-
cantly correlated with a correlation coefficient of 0.673
(p <0.001, R2 0.45). A weaker correlation was seen for
Table 1 Patient demographics (Continued)
S100B (μg/L), third sample Median (IQR) 0.32 (0.15–0.74)
NSE (μg/L), third admission Median (IQR) 17 (12–24)
Patients with NSE hemolysis the first 72 hours n (%) 75 (18)
Outcome
Time to outcome assessment in surviving patients (days) Median (IQR) 368 (339–397)
Glasgow Outcome Score (GOS) GOS1, n (%) 85 (20)
GOS2, n (%) 2 (0.5)
GOS3, n (%) 116 (28)
GOS4, n (%) 126 (30)
GOS5, n (%) 88 (21)
GOS1–3 (Unfavorable), n (%) 203 (49)
GOS4–5 (Favorable), n (%) 214 (51)
Demographics for the included 417 patients categorized in parameters acquired at scene of accident, admission, neuroradiology and biomarker data as well as
long-term outcome. Number of missing samples is listed in the right column
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logged AUC levels the first 48 hours after trauma, yield-
ing a correlation coefficient of 0.613 (p <0.001, R2 0.38).
Parameters correlated to S100B and NSE levels
A univariate analysis revealed that several parameters
were significantly correlated to the levels of NSE and
S100B, as illustrated by Table 4. For multivariate ana-
lysis, the Stockholm SAH score was used instead of
Stockholm CT score, as it provided a higher R2. Several
parameters were independently correlated to NSE levels,
while only pupil unresponsiveness, hypoxemia, and
higher Stockholm SAH score independently predicted
S100B levels. Admission levels for NSE and S100B
exhibited a different profile, with no intracranial CT
parameter being significantly correlated to NSE and
multitrauma being positively correlated to S100B (data
not shown). Using all parameters, including intracranial
variables, the best model explained 0.195 adjusted-R2 of
NSE and 0.161 of S100B, thus concluding that much of
the variance remains unaccounted.
Discussion
To our knowledge, this is the largest retrospective TBI
outcome study including S100B and NSE samples to
date. Moreover, by combining the two proteins in the
analyses, it provides a unique opportunity to elucidate
the properties and clinical utility of these biomarkers.
Doing this we found that both NSE and S100B levels,
per se, independently correlate to long-term functional
outcome in univariate and multivariate models, albeit
Table 2 Univariate outcome prediction
GOS 1–5 (proportional odds analysis)
p value Nagelkerke’s pseudo-R2 (coefficient)
Gender (female) 0.760 0.000 (-)
Age <0.001 0.151 (-, higher age = lower GOS)
Pupil unresponsiveness <0.001 0.074 (-, if present = lower GOS)
Glasgow Coma Score (GCS) <0.001 0.070 (+, higher GCS = higher GOS)
Multitrauma 0.867 0.000 (+)
Hypoxemia 0.040 0.015 (-)
Hypotension 0.494 0.002 (-)
Glucose 0.010 0.022 (-)
Hemoglobin <0.001 0.044 (+)
Head Abbreviated Injury Score (AIS) 0.002 0.029 (-)
Marshall 0.190 0.004 (-)
Rotterdam <0.001 0.048 (-)
Stockholm <0.001 0.132 (-)
Stockholm subarachnoid hemorrhage (SAH) <0.001 0.079 (-)
S100B admission (log) <0.001 0.051 (-)
Neuron-specific enolase (NSE) admission (log) 0.025 0.013 (-)
S100B area under the curve (AUC) 48 h (log) <0.001 0.132 (-)
NSE AUC 48 h (log) 0.001 0.038 (-)
GOS 1–3 vs 4–5 (bivariate regression analysis)
S100B admission (log) <0.001 0.061 (-)
NSE admission (log) 0.096 0.009 (-)
S100B AUC 48 h (log) <0.001 0.127 (-)
NSE AUC 48 h (log) 0.002 0.032 (-)
GOS 1 vs 2–5 (bivariate regression analysis)
S100B admission (log) 0.001 0.054 (-)
NSE admission (log) 0.008 0.027 (-)
S100B AUC 48 h (log) <0.001 0.179 (-)
NSE AUC 48 h (log) <0.001 0.077 (-)
Table illustrating different un-imputed parameters versus different outcome dichotomizations. Nagelkerke’s pseudo-R2 and regression coefficients are shown to fa-
cilitate interpretation. A negative coefficient means that a higher level of the parameter correlated to a lower Glasgow Outcome Score (GOS) (e.g., age) and vice
versa (e.g., GCS). Bold indicates significance (p <0.05)
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Fig. 1 (See legend on next page.)
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S100B providing significantly more accuracy. While pa-
tients with favorable outcome have low and rapidly de-
creasing levels, S100B and NSE levels in patients with
unfavorable outcome remain elevated during a longer
period of time, presumably indicating an ongoing cere-
bral injury. However, in combination NSE did not pro-
vide any additional independent information toward
long-term outcome over S100B. The cause of this is that
despite their neuronal versus glial origin, a high covari-
ance between the two biomarkers is seen. Additionally,
NSE only discriminates mortality, while S100B provides
predictive ability at all levels of GOS. While S100B in-
creased its predictive capabilities if sampled 12–30 h
after trauma, NSE’s predictive capabilities remained low
at all time points, possibly due to a greater influence by
multitrauma or other non-brain contributors to total
serum levels such as hemolysis of erythrocytes ex vivo.
In aggregate, our study suggests a greater clinical utility
of S100B over NSE.
We chose to include all TBI patients that were deemed
to be in need of neuro-intensive care at admission to the
hospital, and not necessarily patients that were uncon-
scious (GCS 3–8), which are usually grouped together
when stratifying TBI patients, and is something that
could be considered a limitation. However, there is a
strong opinion in the TBI community today that using a
symptom to include TBI patients in studies is inad-
equate. A major conclusion of the IMPACT group was
that GCS inclusion criterion could be a contributor to
the many negative clinical trials in the field [53]. This is
exemplified in our study, as several of our moderate-to-
mild patients (GCS 9–15) at admission presented “ser-
ious”, “severe” or even “critical” injuries according to
their Head AIS scores. Moreover, GCS is also hazardous
due its subjective nature [54], as well as its influence
from drugs, ethanol, and sedative agents [55, 56]. In ag-
gregate, we deem that the best inclusion criteria is the
one that is currently used, i.e., that patients who the
(See figure on previous page.)
Fig. 1 a and b illustrate every patient as an individual line with the biomarker S100B (a) and neuron-specific enolase (NSE) (b) on the y-axis and
time after trauma on the x-axis (hours). Colors are corresponding to outcome with darker color indicating a worse outcome, which becomes
more favorable as it gets lighter. c and d are averages of the different GOS groups. As is shown by (a and b), there is limited data after 48 hours
so it should be interpreted with caution. e and f are line plots indicating when to sample a biomarker after trauma to achieve maximum outcome
prediction to long-term GOS1–5. The x-axis shows when in time since the trauma the sample of S100B (e) and NSE (f) was acquired (hours). The
y-axis represents the Nagelkerke’s pseudo-R2 of a prediction model (proportional odds) toward GOS1–5, using either logged S100B (e) or NSE (f).
The pseudo-R2 is calculated in each point using a sliding window incorporating 200 data points in chronological order. If a patient is represented
more than once the sample is averaged, thus retaining independent points. The graph stops at approximately 48 hours as the later data points
will be included in that final measurement. The line represents a locally weighted scatterplot smoothing (LOWESS), which is a nonlinear regression
of the data points in the plots, a bootstrap confidence interval using two standard deviations is provided. Finally, in (g and h), which use the
same method as in (e and f), but here the explained variance (y-axis) is how well the presence of extracranial multitrauma explains the levels of
S100B (g) and NSE (h)
Fig. 2 Conditional density plots of S100B (a) and neuron-specific enolase (NSE) (b) area under curve (AUC) 48 h per Glasgow Outcome Score
(GOS) group. Log biomarker AUC data is provided on the x-axis (μg/L/48 hours). The numbers on the left y-axis represent GOS while outcome
proportions, summing to one is on the right y-axis. An overlay indicates the distribution of S100B and NSE samples
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attending neurosurgeon deem will be in need of neuro-
intensive care and intracranial monitoring for intracra-
nial injuries, and that this represents a clinically valid
NICU TBI patient cohort.
Outcome prediction using S100B and NSE
That our outcome models found NSE levels correlated
to outcome in univariate, as well as independently in
multivariate analyses, is congruent with earlier studies
[57, 58]. However, in contrast to S100B, NSE does not
appear to discriminate between favorable and unfavorable
outcome, but only mortality versus survival, something
that is supported by similar findings in a recent meta-
analysis of NSE [21] and by Vos and co-workers [39].
When compared to NSE, S100B has a higher overall
predictive power, in accordance with other groups ana-
lyzing and comparing both biomarkers [59–61], where
the predictive capability of NSE was found limited in
the presence of S100B in multivariate outcome models
[39, 62]. An explanation is, again, the notable covari-
ance between serum S100B and NSE, which has been
shown to be 0.50–0.78 (correlation coefficient) in previ-
ous studies [39, 58, 63, 64], similar to ours of 0.67.
However, in our study this correlation decreases over
time, highlighting the need for more granular temporal
considerations when assessing biomarkers [65]. That
NSE holds similar information as S100B, suggests that
they are part of a similar pathophysiological process
Table 3 Multivariate outcome prediction models
Parameters included Explained variance (pseudo-R2)
IMPACT Age + pupils + GCS + hypoxemia + hypotension + Hb + glucose
+ Rotterdam CT score
0.298
Core Age + pupils + GCS + hypoxemia + hypotension + Hb + glucose
+ Stockholm CT score
0.316
Core + S100B Age + pupils + GCS + hypoxemia + hypotension + Hb + glucose
+ Stockholm CT score + S100B AUC 48 h
0.379 (p <0.001 vs Core)
Core + neuron-specific enolase (NSE) Age + pupils + GCS + hypoxemia + hypotension + Hb + glucose
+ Stockholm CT score +NSE AUC 48 h
0.344 (p <0.001 vs Core)
Core + (S100B/NSE) Age + pupils + GCS + hypoxemia + hypotension + Hb + glucose
+ Stockholm CT score + (S100B AUC 48 h/NSE AUC 48 h)
0.365 (p <0.001 vs Core)
Core + S100B + NSE Age + pupils + GCS + hypoxemia + hypotension + Hb + glucose
+ Stockholm CT score + S100B AUC 48 h + NSE AUC 48 h
0.379 (p = 0.934 vs Core + S100B)
Table showing the different multivariate models to predict GOS 1–5. Bold indicates which parameters that were independently correlated to outcome in that
specific model. A “Core” model was created, similar to the IMPACT calculator but with Stockholm CT score instead of Rotterdam CT score
Table 4 Parameters correlated to S100B and NSE levels
NSE AUC 48 h S100B AUC 48 h
p value R2 (coefficient) p value R2 (coefficient)
Gender 0.937 0.000 (-) 0.862 0.000 (+)
Age <0.001 *0.028 (-) 0.055 0.009 (+)
Pupil unresponsiveness <0.001 *0.030 (+) <0.001 *0.032 (+)
Glasgow Coma Score (GCS) admission 0.001 0.024 (-) <0.001 0.028 (-)
Multitrauma <0.001 *0.032 (+) 0.202 0.004 (+)
Hypoxemia scene of accident (SoA) 0.015 0.014 (+) <0.001 *0.038 (+)
Hypotension SoA 0.237 0.003 (+) 0.430 0.001 (+)
Glucose admission 0.022 0.012 (+) 0.005 0.018 (+)
Hemoglobin admission 0.072 0.008 (+) 0.258 0.003 (-)
Head Abbreviated Injury Score (AIS) 0.123 0.006 (+) 0.033 0.011 (+)
Marshall CT classification 0.931 0.000 (+) 0.207 0.004 (+)
Rotterdam CT score 0.006 0.018 (+) <0.001 0.045 (+)
Stockholm CT score 0.001 0.029 (+) <0.001 0.060 (+)
Stockholm subarachnoid hemorrhage (SAH) score <0.001 *0.074 (+) <0.001 *0.098 (+)
Model explained (adjusted R2) 0.195 0.161
Table illustrating which parameters that were correlated to S100B and neuron-specific enolase (NSE) levels using linear univariate and multivariate models. Bold
indicates significance (p <0.05). The asterisk (*) highlights which parameters were independently correlated to the levels of each biomarker. Adjusted-R2 and
coefficient are shown to facilitate comparison and interpretation
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despite their separate cellular origins. This contrasts
with, for example, neurofilament light (NF-L), which
has seen to have a much lower covariance with S100B
[31]. In aggregate, while NSE is an independent out-
come predictor in TBI, it does not add any additional
pseudo-R2 in the presence of S100B, which is a better
predictor overall.
Optimal sampling time to assess outcome
Timing of biomarker sampling in studies is not stan-
dardized and much of the differences in findings of stud-
ies may relate to dissimilar sampling times. In this study
we attempt to focus on some little-studied temporal
aspects of these biomarkers. Our results suggest that a
more granular focus on temporal changes may be
needed in biomarker research in general, as important
aspects of characterization may be otherwise lost [65].
The optimal timing of NSE sampling for outcome pre-
diction has acquired insufficient attention earlier. Some
studies have only used one sample at admission [66, 67],
while others have sampled NSE more frequently and no-
ticed that peak levels are better than admission levels for
outcome prediction [18, 62]. We have previously shown
that the outcome predictive power of S100B increased
substantially after about 12 hours [12]. Again, in this
larger cohort, we noticed a similar pattern with an ex-
plained variance toward outcome of about 0.25–0.30
some 30 hours after trauma. However, it must be noted
that this study overlaps patients (2005–2009) with the
current study. In contrast, NSE, exhibits a rather flat
and low predictive power over time, with a pseudo-R2
< 0.10. Presumably, due to the longer half-life of NSE,
NSE will remain elevated for a longer period of time
compared to S100B (30 hours vs 25 minutes) [24, 30].
This, and the fact that hemolysis could presumably
affect NSE over a prolonged period of time, are poten-
tial confounders possibly affecting its predictive cap-
abilities. In summary, both biomarkers are influenced
by multitrauma early after injury, however 10–12 hours
after trauma, S100B’s predictive capability increases
while NSE’s outcome prediction remains relatively low
days after trauma.
Influence of multitrauma on S100B and NSE
In this study, we explored the impact of multitrauma on
NSE and S100B levels over time. We used a sliding win-
dow methodology clearly suggesting that the effect of
multitrauma on S100B is limited to the first 12 hours,
whereas in the case of NSE, the correlation between
NSE and multitrauma remains past 24 hours. Other
studies have found a correlation between NSE and extra-
cranial injury, questioning its validity as a biomarker of
cerebral injury [68, 69]. S100B has also been criticized for
being released from extracranial sources [22, 23, 70–72].
However, our study indicates that the extracranial con-
tribution is probably more problematic for NSE than
for S100B. The washout effect of S100B from extracra-
nial trauma after TBI has been shown to be relatively
fast [23, 70], while in theory, several hematomas con-
taining slowly degrading erythrocytes will be contribut-
ing to the total NSE levels for days or even weeks,
especially given the longer half-life. As can be seen in
Fig. 1h, the multitrauma contribution of NSE is in-
creased past 24 hours, which almost coincides with the
described serum half-life of the protein [24]. Attempts
to adjust for hemolysis in NSE samples have been
made, which have shown to yield more accurate results
[73, 74], something that unfortunately was not possible
in our retrospective approach. In future studies, it
would be of interest to isolate the kind of extracranial
injury that results in the greatest release of NSE, some-
thing that we recently have done with S100B in bicycle
injuries [27]. Moreover, in addition to intra- and extra-
cranial injuries, we found NSE to also be significantly
correlated with age (negative correlation), an observa-
tion that may require further investigation, but we
believe that it is due to the fact that a majority of the
multitrauma patients were younger. In aggregate, NSE
appears more confounded by extracranial trauma than
S100B.
S100B and NSE versus more novel markers of brain injury
More specific protein biomarkers of brain tissue fate in
serum are currently being explored, including, among
others, glial fibrillary acid protein (GFAP) [75, 76], ubi-
quitin C-terminal hydrolase L1 (UCH-L1) [77, 78] and
neurofilament light (NF-L) [31]. While GFAP have been
shown to be less influenced by extracranial injury than
S100B in mild TBI [75], both GFAP [79] and UCH-L1
[80, 81] serum levels have been shown to be elevated in
trauma patients without head injury. As yet, it is difficult
to say if these novel markers are better in predicting out-
come and assessing injury severity, as compared to
S100B and NSE. Vos and co-workers analyzed S100B,
NSE, and GFAP in more severe TBI patients and noted
that all exhibited similar capabilities, albeit S100B being
a somewhat better predictor of mortality [39]. Similar re-
sults have been shown by Pelinka et al. [76], who albeit
found GFAP to be a somewhat more accurate outcome
predictor than S100B. In mild TBI, S100B has been
shown to be a more reliable marker than UCH-L1 as a
predictor of injury severity [82]. More importantly,
GFAP and UCH-L1 have not been as extensively studied
as S100B and NSE in more severe TBI cohorts, and a re-
cent study indicates that UCH-L1 and GFAP may not
add predictive power to commonly used prognostic
models in TBI [83]. Thus, while more brain-specific pro-
teins exist and are being investigated, studies have yet to
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confidently show that they are better predictors of TBI
outcome and severity than S100B and NSE.
In summary, this study suggests S100B to be the more
useful of the two biomarkers for outcome prediction in
NICU TBI patients. It is important to note that our find-
ings cannot be translated to other cerebral pathologies
such as anoxic brain injuries after cardiopulmonary
resuscitation (CPR), or stroke, where NSE is utilized
[84–86]. In TBI cohorts similar to ours, early samples of
both biomarkers should be interpreted with caution as
they are influenced by extracranial trauma. However, in
the case for S100B the extracranial trauma component
appears negligible from 12 hours after injury. While
more brain-specific markers of tissue injury exist, to
date, none have in our opinion yet added more utility
than S100B in TBI patients. We therefore suggest that
future novel biomarkers should be compared with
S100B, and that biomarker evaluation should include
time series analysis elucidating temporal aspects of in-
formation content and possible confounders.
Limitations
There are several limitations to this study that should be
noted. The retrospective nature is associated with some
inherent weaknesses, even if sampling at the NICU was
done prospectively by clinical protocol for all patients. A
total of 593 patients were excluded due to a limited
amount of protein biomarker samples. The cause is
largely due to patients being treated at other ICUs prior
to NICU referral. A majority of these patients did not
reach the NICU in time to have three 12-hourly, samples
acquired within 48 hours of trauma. As previously
noted, the mortality was not higher in this group. Al-
though this clearly affects the cohort composition select-
ing a more severe TBI population with early referrals
and more isolated TBI, we believe that this still repre-
sents a clinically relevant NICU population in which to
study these biomarkers.
There is a potential treatment bias as levels of NSE
and S100B were not blinded to caregivers. While we
have not changed any local guidelines due to NSE or
S100B sampling, secondary peaks of S100B do trigger
further diagnostics and a potential change in the treat-
ment regime [15]. That NSE and S100B are used differ-
entially could affect results, but are in our opinion more
the result of years of experience of these biomarkers
simultaneously where S100B has emerged as the more
clinically comprehensive and consistent biomarker. As
we have used biomarkers from the first 72 hours after
trauma in this study, and consider these levels more cor-
related to the initial traumatic cerebral injury than to
secondary injuries, we believe that treatment bias will
not meaningfully influence conclusions.
An additional limitation is that we could not in retro-
spect adjust for the hemolysis contribution [25], some-
thing that would have been possible if we had a
hemolysis index [74]. The method of ocular inspection
of hemolysis used at the laboratory during this study is
inherently blunt and subjective. It is difficult to define if
the hemolysis index (hemoglobin concentration) is 0.25,
0.50, or even 1.0 g/L hemoglobin in a sample and thus it
is fair to assume that hemolysis probably influenced the
samples resulting in higher total levels of NSE in some
patients. A better hemolysis adjustment may however
lead to an even greater covariance between NSE and
S100B.
Finally, the S100B assay was changed during the ex-
perimental period. While good correlations between the
two methods have been shown [43, 44, 87], others have
shown that there is a discrepancy, especially in concen-
trations above 0.4 μg/L, and that the Elecsys device con-
sistently measured lower levels (i.e., a majority of our
samples were lower than 0.4 μg/L) [88]. In the current
dataset, comparing S100B levels for patients with un-
favorable outcome between the two assays (87 of the
170 patients with the old LIAISON assay vs 116 of the
247 patients with the new Elecsys assay) indicated that
the LIAISON yielded a median peak level of 1.2 (inter-
quartile range: 0.6–2.3) μg/L while the Elecsys assay 1.0
(interquartile range: 0.3–2.9) μg/L of S100B (p = 0.315,
Mann-Whitney U test). Thus, we could not replicate the
significantly lower levels seen in other studies with the
current study material, supporting that the assay change
is a minor limitation.
Conclusions
In this largest cohort of biomarkers NSE and S100B to
date, we found that NSE is independently correlated to
long-term functional outcome in neuro-intensive care-
treated TBI patients, but loses its predictive capabilities
in the presence of S100B, which is a more accurate out-
come predictor in both univariate and multivariate
models. This is due to a strong correlation and thus co-
variance between the two biomarkers, possibly reflecting
a similar pathophysiological process, albeit from differ-
ent cellular origins. Moreover, NSE is seen related to ex-
tracranial trauma up to 48 hours after trauma, whereas
this influence is limited to 12 hours for S100B. In sum-
mary, S100B appears the more useful biomarker of these
two in this population. Additionally, we find it important
to focus future biomarker studies on temporal relation-
ships of information content, and toward that of con-
founders, to better understand and evaluate clinical
utility. Prospective studies are necessary to better, and
with higher accuracy, correlate putative biomarkers to
outcome and injury severity.
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